Lexicon director granted options and RSUs

Lexicon Pharmaceuticals director Ivan Cheung received new equity awards as part of his compensation.

Rhea-AI Filing Summary

Lexicon Pharmaceuticals director Ivan Cheung received new equity awards as part of his compensation. On May 1, 2026, he was granted a stock option for 43,478 shares of common stock at an exercise price of $1.61 per share, expiring on May 1, 2036. This option vests in three equal annual installments over the first three anniversaries of the grant date.

He was also granted 35,714 restricted stock units, each representing a contingent right to receive one share of common stock. These RSUs vest in full on the first anniversary of the grant date. Both awards are reported as directly owned and represent routine, compensation-related acquisitions rather than open-market purchases or sales.

Insider Trade Summary

Grant/Award: 79,192 shares

Grant/Award 2 txns

Insider Cheung Ivan

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Units	35,714	$0.00	$0.00
Grant/Award	Stock Option (Right to Buy)	43,478	$0.00	$0.00

Holdings After Transaction: Restricted Stock Units — 35,714 contracts (Direct); Stock Option (Right to Buy) — 43,478 contracts (Direct)

Footnotes (3)

1. F1. Restricted stock unit vests with respect to 100% of the shares subject to the restricted stock unit on the first anniversary of the grant date.
2. F2. Each restricted stock unit represents a contingent right to receive one share of common stock.
3. F3. Option vests with respect to one third of the shares subject to the option on each of the first three anniversaries of the grant date.

Key Figures

Stock options granted: 43,478 shares Option exercise price: $1.61 per share Option expiration date: May 1, 2036 +3 more

6 metrics

Stock options granted 43,478 shares Option grant to director on May 1, 2026

Option exercise price $1.61 per share Stock option on Lexicon common stock

Option expiration date May 1, 2036 End of exercise period for granted option

Restricted stock units granted 35,714 units RSU grant to director on May 1, 2026

Shares underlying options 43,478 shares Underlying Lexicon common stock for option

Shares underlying RSUs 35,714 shares Underlying Lexicon common stock for RSUs

Key Terms

Restricted stock unit, Restricted Stock Units, Stock Option (Right to Buy), vests, +1 more

5 terms

Restricted stock unit financial

"Restricted stock unit vests with respect to 100% of the shares"

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

Restricted Stock Units financial

"security_title": "Restricted Stock Units""

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Stock Option (Right to Buy) financial

"security_title": "Stock Option (Right to Buy)""

vests financial

"Option vests with respect to one third of the shares"

contingent right financial

"represents a contingent right to receive one share of common stock"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity awards did Ivan Cheung receive from Lexicon Pharmaceuticals (LXRX)?

Ivan Cheung received a stock option for 43,478 shares at a $1.61 exercise price and 35,714 restricted stock units. Both awards relate to Lexicon Pharmaceuticals common stock and were granted as compensation, not purchased in the open market, according to the Form 4 filing details.

How do Ivan Cheung’s new stock options at Lexicon Pharmaceuticals (LXRX) vest?

The 43,478-share stock option vests in three equal annual installments. One third of the shares vest on each of the first three anniversaries of the May 1, 2026 grant date, aligning Cheung’s compensation with longer-term company performance and continued board service over multiple years.

What are the terms of the restricted stock units granted to Ivan Cheung at LXRX?

Ivan Cheung received 35,714 restricted stock units tied to Lexicon Pharmaceuticals common stock. These RSUs vest in full on the first anniversary of the May 1, 2026 grant date, and each unit represents a contingent right to receive one share upon vesting, subject to award conditions.

Are Ivan Cheung’s recent Lexicon Pharmaceuticals (LXRX) Form 4 transactions open-market buys or sales?

The transactions are compensation-related grants, not open-market buys or sales. The Form 4 shows option and restricted stock unit awards coded as “A” for grant or award acquisition, with zero transaction price per share, indicating they were issued by the company as part of his director compensation.

What is the exercise price and expiration date of Ivan Cheung’s new options at LXRX?

The stock option granted to Ivan Cheung covers 43,478 shares of Lexicon Pharmaceuticals common stock at an exercise price of $1.61 per share. According to the Form 4, the option expires on May 1, 2036, giving a long-dated window to exercise once vested.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/04/2026 - 04:30 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cheung Ivan

(Last) (First) (Middle)

2445 TECHNOLOGY FOREST BLVD

11TH FLOOR

(Street)

SPRING TEXAS 77381

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
LEXICON PHARMACEUTICALS, INC. [ LXRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	$0	05/01/2026		A		35,714		(1)	(2)	Common Stock	35,714	$0	35,714	D
Stock Option (Right to Buy)	$1.61	05/01/2026		A		43,478		(3)	05/01/2036	Common Stock	43,478	$0	43,478	D

Explanation of Responses:

1. Restricted stock unit vests with respect to 100% of the shares subject to the restricted stock unit on the first anniversary of the grant date.

2. Each restricted stock unit represents a contingent right to receive one share of common stock.

3. Option vests with respect to one third of the shares subject to the option on each of the first three anniversaries of the grant date.

	/s/ Ivan H. Cheung	05/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)